Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Skin Cells That Stop Replicating (Senescent) During Wound Healing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02755584
Recruitment Status : Recruiting
First Posted : April 29, 2016
Last Update Posted : March 7, 2019
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute on Aging (NIA) )

Brief Summary:

Background:

Cellular senescence is the aging of cells. It is a complex process that may be connected with aging and age-related diseases. It is unknown if these cells appear around wound sites in humans a few days after skin injury and if there are differences in young and old individuals. This study is being done to look at how cells in your body respond to small skin wounds. This information may help treat age-related diseases.

Objective:

To study how cells in the body respond to small skin wounds.

Eligibility:

Healthy adults ages 20-39 or 70+

Design:

Participants will be screened with medical history, physical exam, and blood sample. They will fast before the screening visit. Women will have a urine pregnancy test.

Participants will have 3 study visits over about 3 weeks.

Visits 1 and 2: Participants will fast before and have blood taken. Women will have a urine test. All participants will have 2 skin biopsies. A spot on the upper arm will be numbed. Two small pieces of skin will be removed. They will keep the area covered until the next visit.

Visit 3: Participants will have their vital signs taken. Their biopsy wounds will be measured and photographed.


Condition or disease
Healthy Volunteers

Detailed Description:

Objectives and Specific Aims:

The objective of this proof-of-concept study is to understand the physiological role of senescent cells in humans during the aging process using a model of wound healing. Cellular senescence is the phenomenon by which normal cells cease to divide in response to a stress. We aim to determine if in healthy humans: (1) senescent cells appear around wound sites a few days after skin injury; (2) the number of senescent cells induced by skin injury increases with age; (3) the wound healing process, as determined by the size of the healed wounds, is altered with aging; (4) biomarkers of senescence-associated secretory phenotype (SASP) increase significantly in the tissue around the wound a few days after skin injury, and the magnitude of increase is higher in older compared to younger persons; (5) ethnic differences in the dynamics of the appearance of senescent cells and whether such a difference is associated with wound healing. We also want to describe changes that occur with aging in DNA methylation and histone acetylation, gene expression, and protein expression within senescent cells in comparison to normal tissue.

Experimental Design and Methods:

One hundred and twenty-eight healthy participants, sixty-four between the ages of 20-39 years and sixty-four 70 years old or older will be recruited for this pilot study. Of the sixty-four participants in each age group, thirty-two will be men and thirty-two will be women and sixteen

will be Caucasian and sixteen will be African American. Each participant will have two 3mm skin biopsies on the inner upper arm during baseline visit (Visit 1) and two 6mm skin biopsies concentric to the previous site during Visit 2. Visit 2 will be scheduled on 8 different days (day 3, 5, 7, 9, 11, 13, 21 and 30) after the baseline visit with two men and two woman from each age/ethnic group for each of the days. A follow-up visit will be scheduled at the discretion of the medical staff. Senescent cells will be visualized by confocal microscopy based on a number of senescent markers described in the literature. Senescent biomarkers will be measured in the tissue and systemically at baseline and follow-up.

Medical Relevance and Expected Outcome:

Cellular senescence is a complex process characterized by arrest in replication that is thought to be intrinsically connected with aging and age-related diseases. Recently, researchers have

suggested that senescent cells may play a role in the pathogenesis of type 2 diabetes and its associated complications. Therefore, understanding the physiological role of senescent cells is critically important for understanding aging and age-related diseases such as type 2 diabetes. Preclinical data have shown that senescent cells were inducible during cutaneous wound healing. Our preliminary results showed that there may be a difference in rate of granulation tissue formation with ethnicity. Therefore, this method can be used to quantify

senescent cell response after a standard stimulus and to verify whether the magnitude of senescence response correlate with aging and ethnicity. In the future this method could be used to test interventions that can modify the senescence response, and may be an invaluable method for assessing novel treatments of type 2 diabetes involving senescent cells.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 250 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Pilot Study of Skin Cells That Stop Replicating (Senescent) During Wound Healing
Actual Study Start Date : June 28, 2016
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Group/Cohort
Healthy Volunteers
between the ages of 20-39 years and 70 years old and older



Primary Outcome Measures :
  1. To demonstrate that in humans, senescent cells will appear around wound sites after skin injury. [ Time Frame: Basline visit 1and visit 2 six different days ]
    Understanding the physiological role of senescent cells is critically important for understanding aging and age related diseases. Ourpreliminary results showed that there may be a difference in rate of granulation tissue formation with ethnicity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The study population includes healthy volunteers between the ages of 20-39 years and 70 years old and older. Each age group will be men and women Caucasian and African American.
Criteria
  • INCLUSION CRITERIA:
  • Age 20 - 39 years or age 70 years and older
  • Healthy (see exclusion criteria below)
  • Are able to understand the study risks and procedures, and consent to participate in the study.
  • Are able to read and speak English.
  • Caucasian or Africian American
  • Previous enrolled participants.

EXCLUSION CRITERIA (SCREENING VISIT):

  • A medical condition that requires the use of chronic anticoagulant medication use such as warfarin, clopidogrel, heparin or antiplatelet agents other than low dose aspirin (81mg).
  • History of increased bleeding due to either a known medical condition or an undiagnosed cause.
  • A medical condition that causes impaired wound healing such as diabetes.
  • Current androgenic/anabolic and/or corticosteroid use or use within 90 days of the procedure (ocular corticosteroid use okay).
  • Current antibiotic or anti-viral use or use within 60 days of the procedure.
  • Active infections or chronic skin conditions that would prevent access to the biopsy area.
  • Taking non-steroidal anti-inflammatory agents (NSAIDs) such as Motrin (Ibuprofen), Advil (Ibuprofen) or Naprosyn (Naproxen) and the

participant is unable to stop taking them 3 days before the biopsy and 1 day after the biopsy procedure.

  • Taking more than 81 mg of aspirin a day and the participant is unable to stop taking it for 3 days before the biopsy and 1 day after the biopsy procedure.
  • Allergic to Lidocaine (Xylocaine) or any other local anesthetic or the participant has had in the past a severe allergic reaction to similar drugs.
  • Allergic to topical betadine solution.
  • Severe allergy to adhesives found in tape.
  • HIV virus infection.
  • Hepatitis B or C or exposure within 6 months of visit.
  • History of diabetes (requiring any medical treatment other than diet and exercise) or fasting plasma glucose is greater than or equal to 126 mg/dL or HbA1c greater than or equal to 6.5%.
  • Clinically significant hormonal dysfunction (self-reported or laboratory values out of range. Mild hypothyroidism (TSH < 10 microIU/mL) in participants over 60 is not considered exclusion).
  • Kidney disease (Creatinine >1.5 mg/dl or calculated creatinine clearance < 50 cc/min)
  • Liver disease (Bilirubin > 1.5 mg/dl (unless higher levels can be ascribed to Gilbert s disease); ALT, AST or alkaline phosphatase twice the normal serum concentration)
  • Severe gastrointestinal diseases such as Crohn s disease or ulcerative colitis requiring continuous treatment.
  • History of severe pulmonary disease such as chronic obstructive pulmonary disease (COPD) or asthma requiring continuous medication use.
  • History of severe psychiatric conditions associated with behavioral problems or requiring chronic medical treatment.
  • Currently pregnant or breastfeeding.
  • Participants with history of skin keloid formation during wound healing
  • Current illness that as judged by the study physician substantially increases the risks associated the skin biopsy(s) (active infections, allergies, etc.).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02755584


Contacts
Layout table for location contacts
Contact: Linda M Zukley, Ph.D. (410) 350-3983 zukleylm@mail.nih.gov

Locations
Layout table for location information
United States, Maryland
National Institute on Aging, Clinical Research Unit Recruiting
Baltimore, Maryland, United States, 21224
Contact: NIA Studies Recruitment    410-350-3941    niastudiesrecruitment@mail.nih.gov   
Sponsors and Collaborators
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Principal Investigator: Luigi Ferrucci, M.D. National Institute on Aging (NIA)

Publications:
Layout table for additonal information
Responsible Party: National Institute on Aging (NIA)
ClinicalTrials.gov Identifier: NCT02755584     History of Changes
Other Study ID Numbers: 999916101
16-AG-N101
First Posted: April 29, 2016    Key Record Dates
Last Update Posted: March 7, 2019
Last Verified: February 22, 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute on Aging (NIA) ):
Aging
Senescent Cells